Condition 1: Female Infertility. Condition 2: Male infertility. Female infertility Male infertility
Conditions
Interventions
Intervention 1: Intervention group: the intervention in women will be as follows
supplementation with folate 1 mg/day, vitamin B12 500 mcg/day, vitamin D 1000 IU/day and omega-3 fatty acids 1000 mg/day- At least 4 servings/day from low-pesticide residue fruit and vegetables- maxim
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 42 Years
Inclusion criteria
Inclusion criteria: Age between 18 to 42 years BMI between 20 to 30 kg/m2 Consent to participate
Exclusion criteria
Exclusion criteria: Current or previous (within three months) drug use including oral contraceptive pills, hormone therapy, insulin sensitizers or antidiabetics, weight reducing compounds and dietary supplements History of chronic and endocrine disorders including diabetes and impaired glucose tolerance History of having more than 2 unsuccessful ART cycles Adherence to specific diets or exercise programs Tobacco or alcohol consumption Infertility due to tubal or uteri disorders Consumption of more than two servings of fatty fish per week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate. Timepoint: At the end of the assisted reproductive technology cycle. Method of measurement: The presence of an intrauterine pregnancy confirmed by ultrasound at 6 weeks’ gestation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Endometrial thickness and antral follicle count. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: Transvaginal sonography.;The number of retrieved, metaphase 2 and normal morphology oocytes. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: By embryologist.;Fertilization rate. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: The ratio of oocytes that reached the two-pronucleate (2PN) stage to the number of metaphase II (MII) oocytes.;Embryo formation rate. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: The ratio of embryos to oocytes with two pronuclei.;Embryo grade based on Scott criteria. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: By embryologist.;The number of transferred embryos. Timepoint: At the end of the intervention and within ART cycle. Method of measurement: By infertility specialist.;Biochemical pregnancy rate. Timepoint: At the end of the ART cycle. Method of measurement: ?A serum b-human chorionic gonadotropin level >6 mIU/mL, typically measured 17 days (range,15 to 20 days) after egg retrieval.;Sperm quality parameters. Timepoint: At baseline and at the end of the trial. Method of measurement: By infertility specialist.;Serum folic acid level. Timepoint: At baseline and at the end of the trial. Method of measurement: Electrochemiluminescence immunoassay method.;Serum B12 level. Timepoint: At baseline and at the end of the trial. Method of measurement: Electrochemiluminescence immunoassay method.;Serum vitamin D level. Timepoint: At baseline and at the end of the trial. Method of measurement: ???????????? ???? ?? ?????? ????-???????? ????. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRahele Ziaei
Esfahan University of Medical Sciences
Outcome results
None listed